(Q24202100)

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

Apheresis and selective adsorption plus immunoglobulin treatment in Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

Intravenously Administered Immunoglobulin in the Treatment of Childhood Guillain-Barre Syndrome: A Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

Ten-year prospective study (clinical spectrum) of childhood Guillain-Barré syndrome in the Arabian peninsula: comparison of outcome in patients in the pre- and post-intravenous immunoglobulin eras

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

Severe Guillain-Barré syndrome in childhood treated with human immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

What's new in Guillain-Barré syndrome in 2007-2008?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

Assessment of current diagnostic criteria for Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

Aseptic meningitis associated with high dose intravenous immunoglobulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

Controlled trial prednisolone in acute polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

21 January 2018

Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

Immunotherapy for Guillain-Barre syndrome: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

Indicators of rapid clinical recovery in Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

Nephrotoxicity of intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

Treatment of Guillain-Barré syndrome: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

A Single Intravenous Infusion of Gamma Globulin as Compared with Four Infusions in the Treatment of Acute Kawasaki Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

Plasma exchange for Guillain-Barré syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

Epidemiological study of Guillain-Barré syndrome in south east England

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

Acute renal failure resulting from intravenous immunoglobulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

A clinical prognostic scoring system for Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

Intravenous immunoglobulin therapy for Guillain-Barré syndrome with IgG anti-GM1 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

Plasma exchange in Guillain-Barré syndrome: one-year follow-up. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

Appropriate number of plasma exchanges in Guillain-Barré syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

Complications of intravenous gammaglobulin in neuromuscular and other diseases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

Anaphylaxis with intravenous gammaglobulin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

Pharmacoeconomics of therapy for Guillain-Barré syndrome: plasma exchange and intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

A comparison between IVIg and plasma exchange in Guillain-Barré syndrome: a review and decision analysis of the two treatment modalities.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

Eczematous reactions to human immune globulin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

Comparative study of efficacy of plasma exchange versus intravenous gammaglobulin treatment on acute postinfectious polyradiculoneuropathy: a preliminary report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

Treatment of Guillain-Barré syndrome with high-dose gammaglobulin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

Residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002063.PUB5

7 January 2021

10.1002/14651858.CD002063.PUB5

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

22786476

1 reference

Consolidated OpenCitations Corpus – April 2017